Epigenetic suppression of FANCF, a member of the Fanconi anemia gene family, is now implicated in some ovarian cancers. Might this suppression explain the sensitivity of such cancers to the cross-linking agent cisplatin (pages 568–574)?
This is a preview of subscription content, log in via an institution to check access.
Kimberly Homer
References
Taniguchi, T. et al. Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 9, 568–574 (2003).
D'Andrea, A.D. & Grompe, M. The Fanconi anaemia/BRCA pathway. Nat. Rev. Cancer 3, 23–34 (2003).
Bagby, G.C. Genetic basis of Fanconi anemia. Curr. Opin. Hematol. 10, 68–76 (2003).
Lensch, M.W. et al. Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. Blood (in the press).
Nakanishi, K. et al. Interaction of FANCD2 and NBS1 in the DNA damage response. Nat. Cell Biol. 4, 913–920 (2002).
Howlett, N.G. et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606–609 (2002).
Pellegrini, L. et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420, 287–293 (2002).
Pang, Q. et al. The anti-apoptotic function of Hsp70 in the interferon inducible double-stranded RNA-dependent protein kinase-mediated death signaling pathway requires the Fanconi anemia protein, FANCC. J. Biol. Chem. 277, 49638–49643 (2002)
Shimamura, A. et al. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 100, 4649–4654 (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bagby, G., Olson, S. Cisplatin and the sensitive cell. Nat Med 9, 513–514 (2003). https://doi.org/10.1038/nm0503-513
Issue Date:
DOI: https://doi.org/10.1038/nm0503-513
- Springer Nature America, Inc.
This article is cited by
-
Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer
British Journal of Cancer (2008)